𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A combined single and multiple dose pharmacokinetic study of oral isosorbide-5-mononitrate in healthy volunteers

✍ Scribed by G. Storm; B. Oosterhuis; J. Bron; A. J. Wittebrood; A. P. De Jong; J. H. G. Jonkman

Publisher
John Wiley and Sons
Year
1991
Tongue
English
Weight
596 KB
Volume
12
Category
Article
ISSN
0142-2782

No coin nor oath required. For personal study only.

✦ Synopsis

Pharmacokinetics of 20 mg isosorbide-5-mononitrate (IS-5-MN) after single and multiple administration of two different tablet formulations were investigated in twelve healthy human subjects using an open, randomized, two-way crossover experimental design. Pentacard@ 20 mg tablets were compared with IsmoO 20 mg tablets.

After single-dose administration, both preparations caused a rapid increase in IS-5-MN plasma levels with the peak plasma concentration occurring between 0-5 and 1.5 h.

For both formulations, the mean plasma half-life was found to be approximately 5 h after a single dose. In steady state during multiple dosing (t.i.d. at 8 h dosing intervals), a reduced elimination rate was observed. In line with this observation, the area under the plasma concentration-time curve (AUC) for one 8 h dosing interval during multiple dosing was higher than the extrapolated AUC after a single dose. Based on statistical evaluation of the various relevant pharmacokinetic parameters calculated from the plasma concentrations occurring after single and multiple dosing, the tablet formulations are judged to be bioequivalent. KEY w o w Isosorbide-5-mononitrate Nitrates Pharmacokinetics Single dose Multiple dose Relative bioavailability PentacardB Ismo@

πŸ“œ SIMILAR VOLUMES

Single- and multiple-dose pharmacokineti
Single- and multiple-dose pharmacokinetics of oral dolasetron and its active metabolites in healthy volunteers: part 2
✍ Dan C. Dimmitt; Youn Sung Choo; Lorene A. Martin; Thangam Arumugham; William F. πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 132 KB πŸ‘ 2 views

The single-and multiple-dose pharmacokinetics and dose-proportionality of oral dolasetron and its active metabolites over the therapeutic dose range was investigated in 18 healthy men. In an open-label, randomized, complete three-way crossover design, each subject received three separate doses: 50,

Pharmacokinetics of reboxetine in health
Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding
✍ D. M. F. Edwards; C. Pellizzoni; H. P. Breuel; A. Berardi; M. G. Castelli; E. Fr πŸ“‚ Article πŸ“… 1995 πŸ› John Wiley and Sons 🌐 English βš– 885 KB

## Abstract The pharmacokinetics of reboxetine, a new antidepressant agent, were found to be close to linear in a crossover study comparing administration of single 2, 3, 4 and 5 mg capsule doses in 15 healthy male volunteers, and in the same study the capsules were bioequivalent to the proposed th

Pharmacokinetic and safety profile of tr
Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers
✍ Luis Almeida; Manuel Vaz-da-Silva; AmΓ­lcar FalcΓ£o; Eva Soares; Raquel Costa; Ana πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 277 KB

## Abstract This was a double‐blind, randomised, placebo‐controlled study to investigate the pharmacokinetics and safety of __trans__‐resveratrol. In four groups of ten healthy adult subjects (five males and five females), two subjects were randomized to receive placebo and eight subjects to receiv

PHARMACOKINETICS OF REBOXETINE IN HEALTH
PHARMACOKINETICS OF REBOXETINE IN HEALTHY VOLUNTEERS. SINGLE AGAINST REPEATED ORAL DOSES AND LACK OF ENZYMATIC ALTERATIONS
✍ C. Pellizzoni; I. Poggesi; N. P. JΓΈrgensen; D. M. F. Edwards; E. Paus; M. Stroli πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 568 KB

The pharmacokinetics of reboxetine have been investigated in 12 healthy male volunteers after a single 2mg dose of reboxetine and at steady state, following the last administration of a multiple-dose regimen (2mg twice a day for 54d). Reboxetine was analysed in plasma and urine samples collected up